Omisafe Plus 250mg/125mg Injection
Marketer
Innovative Pharmaceuticals
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Omisafe Plus 250mg/125mg Injection
Combiflox 250 mg/125 mg Injection is a dual-action antibiotic, indicated for diverse bacterial infections. Its mechanism combats microbial proliferation, thereby halting infection spread. Administration must be solely under a physician's guidance. Consistent adherence to the prescribed dosage schedule is crucial; completing the full course is vital, even with symptom improvement. Premature cessation may compromise efficacy. Commonly reported side effects include nausea, vomiting, diarrhea, and dyspepsia. Worsening side effects warrant immediate medical attention. Allergic reactions (skin rashes, itching, edema, respiratory distress) necessitate prompt emergency care. Prior to commencing treatment, inform your doctor about all concurrent medications. Pregnant or lactating individuals should seek medical counsel before use. Alcohol consumption should be avoided due to potential additive drowsiness. While generally not affecting driving ability, avoid driving if experiencing somnolence or vertigo. Adequate rest, nutritious food, and ample hydration promote faster recovery. Your physician may order laboratory tests to monitor therapeutic response.
Uses of Omisafe Plus 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Omisafe Plus 250mg/125mg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Omisafe Plus 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Omisafe Plus 250mg/125mg Injection:
Administering this medication will be handled by your physician or registered nurse; self-medication is strictly prohibited.
How Omisafe Plus 250mg/125mg Injection works:
Ceftriaxone and Sulbactam, combined as Omisafe Plus 250 mg/125 mg Injection, offer a dual antibiotic approach. Ceftriaxone's antibiotic action disrupts bacterial cell wall synthesis, hindering their survival. Sulbactam, a beta-lactamase inhibitor, complements this by countering bacterial resistance mechanisms, thus maximizing Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no reported adverse reactions from co-administering Omisafe Plus 250 mg/125 mg Injection and alcohol.
PregnancySAFE IF PRESCRIBED
The injectable formulation Omisafe Plus, 250 mg/125 mg, is typically deemed safe for pregnant individuals. Preclinical trials in animals revealed minimal or no harm to fetuses; nevertheless, data from human trials are scarce.
Breast feedingCAUTION
The administration of Omisafe Plus 250 mg/125 mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment course and until the medication is fully cleared from her system.
DrivingUNSAFE
The administration of Omisafe Plus 250 mg/125 mg Injection can induce drowsiness, visual disturbances, and dizziness. Driving should be avoided if these effects manifest.
KidneyCONSULT YOUR DOCTOR
Data regarding Omisafe Plus 250 mg/125 mg Injection use in patients with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
The injection Omisafe Plus (250 mg/125 mg) requires careful administration in individuals with severe hepatic impairment; dosage modification may be necessary. Seek medical advice. Dosage alteration for Omisafe Plus (250 mg/125 mg) injection is not advised for those with mild to moderate liver dysfunction.
What if you forget to take Omisafe Plus 250mg/125mg Injection :
Should you forget a dose of Omisafe Plus 250 mg/125 mg Injection, seek medical advice.
Facts to Know About Omisafe Plus 250mg/125mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Anti-infective Agents |
3,018 People bought this recently